VahatiCor Secures $23M Series B Financing Led by S3 Ventures and Intuitive Ventures to Advance A-FLUX Reducer for Coronary Microvascular Dysfunction

VahatiCorAnnounced the completion of a $23 million Series B financing round. This round was led by S3 Ventures, with participation from Intuitive Ventures and a strategic investor. The proceeds will be used to accelerate participant recruitment for the SERRA-I study, advance engineering development, and prepare for subsequent research, including pivotal trial planning and regulatory submissions.

Investor Evaluation

"We believe that VahatiCor's A-FLUX represents a significant breakthrough for a large patient population lacking effective treatment options. The company’s unique approach, utilizing a retrievable self-expanding device, offers notable advantages in procedural safety and efficacy, positioning it to become a leader in the field of coronary sinus therapy."

---Brian R. Smith  Managing Director of S3 Ventures

"The high symptom burden of recurrent angina, reduced exercise tolerance, deteriorating quality of life, and the psychological distress caused by delayed diagnosis urgently call for increased clinical attention and the development of effective therapies centered on patient experience. A-FLUX by VahatiCor is precisely the kind of disruptive, patient-centered innovative technology we are committed to supporting. We firmly believe that the company has the capability to follow the necessary clinical pathways and bring this long-awaited treatment to market."

---Terri Burke  Intuitive VenturesSenior Partner

Executive Evaluation

"Securing this round of financing from a renowned investment institution is a significant recognition of our therapy's value proposition and team strength. The company will continue to advance through strategic key phases, refining the A-FLUX therapy via clinical research, and fulfilling our mission to make breakthrough treatments accessible to millions of patients worldwide suffering from coronary microvascular dysfunction. We are deeply proud and excited to be committed to developing interventional treatment solutions that deliver substantial clinical benefits, alleviate symptoms, and improve quality of life for millions of patients globally."

---Marwan Berrada-Sounni  Co-founder of VahatiCor

Coronary Microvascular Dysfunction: A Common but Often Overlooked ConditionCoronary microvascular dysfunction is a common yet frequently overlooked condition, affecting millions of patients worldwide. In the United States alone, 3 to 4 million men and women exhibit signs or symptoms of myocardial ischemia without obstructive coronary artery disease. This condition predominantly affects women, and studies on women with ischemic heart disease but no coronary obstruction show that their annual rate of major adverse cardiovascular events is higher than in matched control groups. Patients with impaired coronary flow reserve or microvascular dysfunction face a 2 to 4 times greater risk of such events. Current anti-anginal drugs have limited efficacy, with over half of the patients continuing to experience symptoms, and there are currently no therapies that directly improve coronary flow reserve. The condition leads to high utilization of healthcare resources and treatment costs, with patients frequently hospitalized and undergoing numerous coronary examinations at rates and severity comparable to those with obstructive coronary artery disease.

For this reason, Johnson & (Shockwave) Create aHourglass ShapeAngina PectorisStent---Shockwave Reducer, the same as implanted into the coronary artery,Can narrow the coronary sinus,Optimize and redistribute oxygenated blood flow, thereby supporting and enhancing perfusion to alleviate angina symptoms. Clinical studies (REDUCER-I) DisplayShockwave ReducerAfter TreatmentContinuous safety and efficacy, andCCS and QoLThe positive improvement lasted for 3 years.

SeePositive Efficacy of Shockwave ReducerSubsequentlyVahatiCorInnovative companies such as VahatiCor, Inc. are actively following up.VahatiCorIs currently the closest-following company, which has already initiated clinical research. ThereforeVahatiCorHas also become a darling of capital.

A-Flux ReducerIt is a minimally invasive self-expanding stent designed to restore natural blood flow and relieve pressure, heaviness, and tightness in the chest.

A-Flux ReducerByWoven from nickel-titanium alloy, designed in an hourglass shape.Adopting SwiftCell design, its design features:

• Variable Cell Structure

• Hourglass Shape

• Shape Memory Materials

VahatiCorVahatiCor, Inc. is an innovative medical device company and a member of T45 Labs. It is committed to advancing the field of medical technology by creating innovative solutions to address unmet clinical needs and improve care standards.